

Candidate: Regional Secretary, North America (2023-2026)



Cheryl Cox, BSc, MT(ASCP), CSSMBB

Director Operations Cell Therapy
Moffitt Cancer Center
United States

Summary of academic and professional background:

I am the Cell Therapies Operations Director at the Moffitt Cancer in Tampa Florida. I have provided leadership for cellular therapy facilities for eight years. I attended the University of Evansville receiving a degree in Clinical Laboratory Sciences. I am board certified by the American Society of Clinical Pathology as a Medical Technologist Generalist and Supervisor. I started her career in cardiovascular research at Bristol Myers Squibb. She eventually transferred into Immunology research at BMS. During subsequent years, Cheryl worked at a Clinical Research Organization, a cord blood biotech, a viral vector facility, a cord blood bank and in correlative studies. I Have over 20 years of management experience with 11 years in cGMP programs. At Moffitt worked on the production of various cellular therapies clinical trial products, overseen BMT Standard of Care and the implementation of commercial FDA approved products. I am an approved FACT auditor, a Lab committee member of ISCT and an active member of SITC.

Affiliated professional and commercial associations and any perceived or potential conflict of interests:

SITC member, ISCT member, ISCT Lab Practice Committee, ISCT Mentor, FACT Inspector, AABB member. No conflict of interests.

List of top notable contributions to the field (e.g. publications, patents, reports, products advanced to clinical trial or regulatory approval, asset development, mergers, acquisitions, etc.) from the last 10 years:

John E. Mullinax, Maclean Hall, Sangeetha Prabhakaran, Jeffrey Weber, Nikhil Khushalani, Zeynep Eroglu, Andrew Brohl, Joseph Markowitz, Erica Royster, Allison Richards, Valerie Stark, Jonathan S. Zager, Linda Kelley, Cheryl Cox, Vernon K. Sondak, James Joseph Mule', Amod Ashok

Sarnaik, Shari Pilon-Thomas: Combination of Ipilimumab and Adoptive Cell Therapy with Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma, Front. Oncol., 02 March 2018

Landin, A. M., Cox, C., Yu, B., Bejanyan, N., Davila, M., Kelley, L. Expansion and Enrichment of Gamma-Delta ($\gamma\delta$) T Cells from Apheresed Human Product. J. Vis. Exp. (175), e62622, doi:10.3791/62622 (2021).

Journal: Cytotherapy

Title: Assessment of the LOVO device for final harvest of novel cell therapies: A Production Assistance for Cellular Therapies (PACT) multicenter study

Corresponding Author: Dr. David McKenna

Co-Authors: Laarni Ibenana; Robert Anderson, PhD; Adriana Brooks; Cheryl Cox; Adrian Gee, PhD; Margaret Gilbert; Joshua Hare, MD; Ugochi Ibekwe; Linda Kelley, PhD; Aisha Khan; Natalia Laptiva; Aaron Orozco, PhD; David Styers; Darin Sumstad

Accepted to Clinical Cancer Research

Manuscript DOI: 10.1158/1078-0432.CCR-22-2103

Manuscript ID: CCR-22-2103R1

Manuscript Title: Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma

Published by: AACR

MacLean Hall, John Mullinax, Cheryl Cox, Amy Hall, Matthew Beatty, Jamie Blauvelt, Patrick Innamarato, Luz Nagle, Holly Branthoover, Doris Wiener, Benjamin Schachner, Alberto Martinez, Allison Richards, Carolyn Rich, Marjorie Colón Colón, Michael Schell, Jamie Teer, Nikhil Khushalani, Jeffrey Weber, James Mule, Vernon Sondak, Shari Pilon-Thomas, and Amod Sarnaik

Summary of involvement with ISCT in the past five years:

I have been involved in the ISCT Mentoring program for the last three years. I have been on the ISCT Lab Practice Committee for the last two years. I have presented in an ISCT sponsored webinar, chaired a round table at the May, 2022 meeting as well as participated in another round table. I also spoke at the Commercial ISCT Signature Series of the May 2022 meeting. I have prepared a Telegraft for the ISCT Mentoring program and participated in oversight of the LPC Lifeline. Lastly, I have attended the last four meetings.

Summary of strategic vision for the Global Society:

I believe that ISCT is vital to the Cell Therapy Community. The wealth of knowledge, research experiences, and understanding available must be shared across organizations and impact all levels of staffing. The academic facilities, biotech, stem cell institutes, cord blood organization, and clinical research areas can all benefit from ISCT. I would like to contribute to advancing membership to all areas while expanding the knowledge base of the organization. I believe that my position in a Cell Therapy Facility which services BMT, Clinical Trials, and acts as a manufacturing facility provides contact, context, and opportunity to assist in this endeavor.